Developmental Cell Death and Oxidative Stress

Endogenous zinc mediates apoptotic programmed cell death in the developing brain

Endogenous zinc can mediate the apoptotic programmed cell death (PCD) in the developing brain. Intensive accumulation of labile zinc occurs in almost all neurons undergoing PCD in the developing rat brain. Based on the greater frequency of neurons with intensive zinc accumulation compared to apoptotic neurons, it is inferred that cytosolic zinc accumulation precedes apoptotic PCD. To determine the role of intracellular labile zinc in developmental apoptosis, we subcutaneously injected the membrane-permeant zinc chelator, N,N,N',N-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN) into postnatal rats for 7 days after birth. TPEN chelated intraneuronal zinc without modulating the expression of the zinc-regulating proteins, ZnT-1, ZnT-3, and synaptophysin. The frequency of apoptotic neurons significantly decreased in TPEN-treated rat brains compared with that in normal postnatal rats. Activating cleavages of caspase-9 and -3, and mitochondrial pro-apoptotic Bax expression were reduced, whereas expression of anti-apoptotic Bcl-2 was increased. Thus, intracerebral zinc chelation may arrest PCD in the developing brain by interfering with the caspase-dependent apoptotic pathway. The present study demonstrates that intracellular zinc acts as a key mediator of developmental apoptosis and therefore provides the first in vivo evidence that endogenous labile zinc causes neuronal apoptosis.

Pathological apoptosis in the developing brain

More than half of the initially-formed neurons are deleted in certain brain regions during normal development. This process, whereby cells are discretely removed without interfering with the further development of remaining cells, is called programmed cell death (PCD). The term apoptosis is used to describe certain morphological manifestations of PCD. Many of the effectors of this developmental cell death program are highly expressed in the developing brain, making it more susceptible to accidental activation of the death machinery, e.g. following hypoxia-ischemia or irradiation. Recent evidence suggests, however, that activation and regulation of cell death mechanisms under pathological conditions do not exactly mirror physiological, developmentally regulated PCD. It may be argued that the conditions after e.g. ischemia are not even compatible with the execution of PCD as we know it. Under pathological conditions cells are exposed to various stressors, including energy failure, oxidative stress and unbalanced ion fluxes. This results in parallel triggering and potential overshooting of several different cell death pathways, which then interact with one another and result in complex patterns of biochemical manifestations and cellular morphological features. These types of cell death are here called "pathological apoptosis," where classical hallmarks of PCD, like pyknosis, nuclear condensation and caspase-3 activation, are combined with non-PCD features of cell death. Here we review our current knowledge of the mechanisms involved, with special focus on the potential for therapeutic intervention tailored to the needs of the developing brain.